ALLY vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Ally Financial exhibits a stable health profile with a Piotroski F-Score of 4/9 and is significantly undervalued relative to its Graham Number ($47.52) and Intrinsic Value ($69.33). The company shows explosive earnings growth (265.4% YoY) and a highly attractive Forward P/E of 6.67 and PEG of 0.47. While low ROE (5.8%) and a bearish technical trend (0/100) present short-term headwinds, the fundamental valuation gap provides a substantial margin of safety. The stock is currently trading below book value (P/B 0.99), suggesting a strong entry point for value-oriented investors.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
ALLY vs JPM: Head-to-Head Comparison
This page compares Ally Financial Inc. (ALLY) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.